Daily Archives: January 9, 2018


Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds

Southborough, MA, January 9, 2018 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, announced today that its patent application for oral compositions of ketamine and related compounds was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The U.S. patent will not expire until after 2033. “This new patent directed toward Amorsa’s anticipated commercial formulations marks another significant accomplishment for the company,” said Dr. Alex Nivorozhkin, COO of Amorsa and co-inventor on this patent. “There’s tremendous commercial potential for Amorsa’s technology to treat several nervous More